Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia Approximately 10-15% of pediatric patients with acute lymphoblastic leukemia (ALL) have a T-cell phenotype. The prognosis of these patients has improved over the last years, owing to the use of more intensive treatment strategies. 1 Characterization of molecular alterations with prognostic impact in T-ALL may be of great help for an early identification of patients at high risk (HR) of failure in whom more intensive treatments, including allogeneic hematopoietic stem cell transplantation, may be considered.
PICALM (clathrin-assembly protein-like lymphoid myeloid leukemia gene)-MLLT10 (formerly CALM-AF10) results from a recurring t(10;11)(p13;q14-21) chromosomal translocation and is the most frequent fusion transcript detected in patients with T-ALL, at an overall rate of 10%, including both adults and children. 2 This translocation fuses PICALM (or CALM) and MLLT10 (also called AF10). The Groupe Franc¸ais de Cytogé né tique Hé matologique firstly observed this translocation in a patient with histiocytic lymphoma. 3 The immunophenotypic characterization of the leukemic cell bearing this fusion gene showed that mature PICALM-MLLT10-positive cases expressed CD5, T-cell receptor (TCR) g/d and CD4 or CD8 (or both), whereas immature cases, which are currently defined as early-T, expressed few T-lineage markers other than CD5, TdT, cCD3 and CD7, and were often positive for CD13, CD33 or CD34. 4 The presence of PICALM-MLLT10 has been associated with a poor prognosis and several studies included very few children with T-ALL. [4] [5] [6] [7] We analyzed a large cohort of children with T-ALL, enrolled in two subsequent AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) protocols, with the aim of evaluating both incidence and prognostic impact of PICALM-MLLT10. Characteristics of the 187 evaluable children with T-ALL are listed in Table 1 ; of them, 14 children (7.5%) were positive for PICALM-MLLT10 and their characteristics are listed in Supplementary Table 1 .
The PICALM-MLLT10 fusion transcript was detected more frequently in males (12 out of 14). Patient's median age was 7 years (range 2-13). PICALM-MLLT10-positive cases were more likely to present with HR features, including a white blood cell (WBC) count higher than 100 000/ml (n ¼ 8).
1,8 PICALM-MLLT10 fusion transcript was significantly more frequent in patients with cortical and mature T, than in those with early-T immunophenotype (P ¼ 0.02). Eight patients were 'poor prednisone (PDN) responders' (PPR), which, by study design, were assigned to the HR group. Based on MRD levels, in the PICALM-MLLT10-positive group, eight children were presented with an intermediate risk pattern and six children with an HR pattern (including three who also were PPR).
Based on the type of steroid given in induction, nine children with PICALM-MLLT10-positive T-ALL were treated with PDN and five children were treated with dexamethasone (DXM). Among the PICALM-MLLT10-negative patients, DXM was given to 53 (30%) out of 173 children treated on both AIEOP-BerlinFrankfurt-Munster ALL-2000 (n ¼ 38) and AIEOP R-2006 (n ¼ 15) studies, respectively. Details on patients' outcome are shown in Supplementary Table 2 .
The relapse rate was similar in both PICALM-MLLT10-positive and negative patients. In the group of PICALM-MLLT10-positive patients, relapse occurred in four patients (21.5%) and involved the central nervous system in three: this proportion appears to be higher than in the PICALM-MLLT10-negative counterpart (5.8%; P ¼ 0.02).
There was no statistically significant difference in terms of final outcome between PICALM-MLLT10-positive and -negative patients, the 5-year event-free survival (EFS) being 71.4% (SE 12.1) vs 62.5% (SE 3.8) (P ¼ 0.53), respectively (Figure 1a) . Consistently, cumulative incidence (CI) of relapse was very similar, as shown in Figure 1b . Same results were obtained after adjusting for risk group in a Cox model (data not shown).
When the analysis was restricted to the subgroup of patients with cortical or mature immunophenotype, which included the majority of PICALM-MLLT10-positive patients (n ¼ 12), there was no statistically significant difference between PICALM-MLLT10- Letters to the Editor positive and -negative patients, the 5-year EFS being 66.7% (13.6) and 74% (4.9), respectively (Supplementary Figure 1) .
Literature on PICALM-MLLT10 issue is quite limited and, to date, no definitive conclusions have been drawn on the incidence and the prognostic impact of this fusion transcript among children with T-ALL. In a previous study of 144 patients with T-ALL, the 20 cases bearing PICALM-MLLT10 fusion transcript, ranging from 3 to 43 years of age (mean, 20.7), were more frequently males (M/F ¼ 2.8), and had a very high WBC count (mean, 94 Â 10 9 /liter); 8 of the 20 had a mediastinal mass, suggesting a tendency of this form of leukemia to involve extramedullary sites, confirmed by our findings. 4 PICALM-MLLT10 fusion transcript was present in 12 of 29 cases with an immature T-cell receptor g/d phenotype, and 8 of 32 cases with a T-cell receptor g/d phenotype, but in none of the 78 a/b or IMb T-cell ALLs. Although the numbers were small, patients with a PICALM-MLLT10 fusion transcript and an immature phenotype had a poor prognosis. Only eight of these 20 cases were children (aged less than 16 years), and the three of them presented with an immature phenotype had a poor prognosis. 4 In a retrospective study of patients treated according to DCOG and COALL protocols, 72 and 55 children with T-ALL, respectively were included. 6 Of them, only three cases harboring the PICALM-MLLT10 fusion transcript, all from DCOG, were reported: all of the three patients relapsed 9, 19 and 22 months after diagnosis and subsequently died. 6 Moreover, the FRALLE group molecularly analyzed 92 cases among 200 children with T-ALL. 9 PICALM-MLLT10 fusion transcript was found in four out of 84 tested children (4.7%), confirming the association with hyperleukocytosis and mediastinal involvement, with one case relapsing. 9 From a biological point of view, PICALM-MLLT10-positive T-lineage leukemia was included in the so called 'HOXA gene cluster (HOXA@)', together with T-ALL bearing MLL rearrangements, inversions on chromosome 7, that is, inv(7)(p15q35) and del(9)(q34.11q34.13), which generates SET-NUP214 fusion product. 10 HOXA gene activation by PICALM-MLLT10 depends on recruitment of the histone H3 methyltransferase hDOT1L by MLLT10.
11 Consistently, a very recent study showed that treatment of MLL-MLLT10 and PICALM-MLLT10 transformed cells with a specific small-molecule inhibitor of Dot1l, suppressed expression of leukemogenic genes such as Hoxa cluster genes and Meis1, and selectively impaired proliferation of MLL-MLLT10 and PICALM-MLLT10-transformed cells. 12 Another recent study reported on 20 patients with PICALM-MLLT10-positive acute leukemias and demonstrated that genes located centromeric to MLLT10 on chromosome 10 in PICALM-MLLT10-positive patients (BMI1, COMMD3, DNAJC1 and SPAG6) are highly expressed, showing that the differential regulation of these genes is not a consequence of the translocation, but rather a result of the expression of the PICALM-MLLT10 fusion protein. 13 Moreover, PICALM-MLLT10-positive T-ALL is associated with EZH2 gene mutations in 27% of cases, showing a distinct gene expression signature. 14 In our experience, the detection of PICALM-MLLT10 fusion transcript occurs in 7% of children with T-lineage ALL and is not associated with a poorer outcome for patients treated with contemporary, intensive chemotherapy. In the light of the recent evidence that lymphoproliferative diseases with EZH2-activating mutations may be addressed to target therapy,
